Stock Updates

A look at a High Market Cap Stock: Valeant Pharmaceuticals International, Inc., VRX

Valeant Pharmaceuticals International, Inc., VRX is in the exchange NYSE and its industry is Drug Delivery in the sector of Healthcare. Based in Canada, Valeant Pharmaceuticals International, Inc., VRX  has a market cap of 10550.65. Since its IPO date on the 3/30/1994, Valeant Pharmaceuticals International, Inc., VRX performance year to date is -69.96%. Today Valeant Pharmaceuticals International, Inc., VRX has gained 3.37%, with a current price of 31.57.

Ownership of the company is 2.30% for insider ownership while institutional ownership is 66.80%. The management of the company have seen the company have a payout ratio of *TBA. Return of assets are at -2.00%, with return on investment at 3.70%.

In terms of debt levels and profit levels, Valeant Pharmaceuticals International, Inc., VRX is seeing a long-term debt/equity of 5.81. While Total debt/equity is 5.87. With a profit margin of -9.60%, this is combined with a gross margin of 74.70%, and operating margin of 7.70%. Valeant Pharmaceuticals International, Inc. ability to meet debt levels, with a current ratio of 1.4, while the quick ratio is 1.1.

For the last year Valeant Pharmaceuticals International, Inc., VRX has seen a EPS growth of -133.00%. A performance for the year of -86.12%. The 52-week high is -87.16%, and the 52-week low is 70.19%. The average volume for Valeant Pharmaceuticals International, Inc., VRX is 26398654.

With a target price of 44.39, can Valeant Pharmaceuticals International, Inc., VRX reach this target? Looking at the value indicators of Valeant Pharmaceuticals International, Inc., VRX. Valeant Pharmaceuticals International, Inc. has a P/E of *TBA and a forward P/E of 3.92. Perhaps the more useful indicator than P/E, is PEG which has a value of *TBA. Valeant Pharmaceuticals International, Inc. also has a P/S and a P/B of 1.02 and 1.99 respectively. For P/cash, Valeant Pharmaceuticals International, Inc. has a value of 12.38, while it is 8.1 for P/free cash flow.

At the current price of 31.57, Valeant Pharmaceuticals International, Inc. has a dividend yield of *TBA. We see a return on equity of -17.00%.

Looking more long-term Valeant Pharmaceuticals International, Inc., is projected to get an EPS growth for the next five years of 11.07%. In the short-term an EPS growth of 19.24% in the next year is forecasted. This is after a EPS growth of -133.00% for this year and for the last five years a 4.40% growth has been seen.

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.

About the author

Mark Hines

Leave a Comment